2. Treatment within 28 days of Cycle1 Day1: Any other systemic therapy for prostate cancer (with the exception of LHRH agonists and LHRH antagonists for testosterone suppression, and bisphosphonates and RANK-ligand inhibitors for bone metastases which are allowed). --Any other investigational product --Any medications listed in Appendix H.